Analyzing the Evidence For The Convalescent Plasma EUA

The justification President Trump used is not directly mentioned in the decision memo, but other data suggests a less-than-overwhelming case for granting emergency use authorization.

Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
The FDA used several kinds of evidence to make its decision on the convalescent plasma EUA. • Source: Shutterstock

US Food and Drug Administration officials agreed there is enough evidence that convalescent plasma “may be effective” and warranted an emergency use authorization, but argued more definitive data is necessary to pinpoint efficacy and the optimal populations that could benefit.

In a clinical memo, agency officials outlined the different and sometimes conflicting evidence that fed into its decision to...

More from Product Reviews

More from Pink Sheet